Sign In
Buy AVIR
$4.70
-0.0400 (-0.84%)
At Close: Jul 31, 2026
All You Need to Know About Atea Pharmaceuticals (AVIR) Rating Upgrade to Buy
01:01pm, Monday, 12'th Aug 2024
Atea Pharmaceuticals (AVIR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year?
10:42am, Monday, 12'th Aug 2024
Here is how Atea Pharmaceuticals, Inc. (AVIR) and Novo Nordisk (NVO) have performed compared to their sector so far this year.
Atea Pharmaceuticals, Inc. (AVIR) Q2 2024 Earnings Call Transcript
12:13pm, Sunday, 11'th Aug 2024
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR ) Q2 2024 Results Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Jonae Barnes - Senior Vice President of Investor Relations and Corpora
Atea Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call on August 7, 2024
07:00am, Wednesday, 31'st Jul 2024
BOSTON, July 31, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral
Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference
07:00am, Wednesday, 29'th May 2024
BOSTON, May 29, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral t
Presentations to Include New Antiviral Efficacy Results, Including SVR12 Data, from Lead-In Cohort of Ongoing Phase 2 HCV Trial
Atea Pharmaceuticals, Inc. (AVIR) Q1 2024 Earnings Call Transcript
10:00pm, Tuesday, 14'th May 2024
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR ) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Jonae Barnes - Senior Vice President of Investor Relations and Corporate Communi
Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024
07:00am, Monday, 29'th Apr 2024
BOSTON, April 29, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral thera
Enrollment Reached Over 2,200 High-Risk Patients in Bemnifosbuvir Monotherapy Cohort Results from SUNRISE-3 Expected in 2H'24 BOSTON, March 27, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nas
Atea Pharmaceuticals, Inc. (AVIR) Q4 2023 Earnings Call Transcript
11:24pm, Wednesday, 28'th Feb 2024
Atea Pharmaceuticals, Inc. (AVIR) Q4 2023 Earnings Call Transcript
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
04:05pm, Wednesday, 28'th Feb 2024
Final Results Confirm 98% Sustained Virologic Response Rate at Week 4 Post-Treatment (SVR4) from Lead-in Cohort in Phase 2 HCV Study
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024
07:00am, Wednesday, 21'st Feb 2024
BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral
Atea Pharma (AVIR) Gains on Upbeat Initial Data From HCV Study
10:31am, Wednesday, 10'th Jan 2024
Atea Pharma (AVIR) gains 11% after reporting positive initial results from the first 52 patients in the lead-in cohort of the mid-stage study evaluating its bemnifosbuvir/RZR combo to treat HCV.
A 98% Sustained Virologic Response at Week 4 (SVR4) Post-Treatment Observed in Initial Data From 52 Patients in Lead-In Cohort in Phase 2 HCV Study
Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
07:00am, Wednesday, 03'rd Jan 2024
BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral
